Pharmacodynamics of natalizumab extended interval dosing in MS

OBJECTIVE: To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5–8 weeks) over 18 months is able to be maintained in the range considered adequate to sustain the clinical efficacy of NTZ. METHODS: In a cross-sectional assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhovtis Ryerson, Lana, Li, Xiaochun, Goldberg, Judith D., Hoyt, Tamara, Christensen, Angel, Metzger, Ryan R., Kister, Ilya, Foley, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057061/
https://www.ncbi.nlm.nih.gov/pubmed/32019876
http://dx.doi.org/10.1212/NXI.0000000000000672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057061/
https://www.ncbi.nlm.nih.gov/pubmed/32019876
http://dx.doi.org/10.1212/NXI.0000000000000672

Ejemplares similares